Beijing, China-Recently, the Beijing Customs Advanced Certification Enterprise Policy Seminar, and Award Ceremony was held in Beijing. Customs authorities and 65 relevant enterprises participated in the event. Gan & Lee Pharmaceuticals (Stock code: 603087. SH), as one of the enterprises newly certified with AEO certification in 2023, attended the meeting and received the honor on-site. This not only means that Gan & Lee has officially become a customs "VIP" but also marks international recognition and trust in Gan & Lee's supply chain management, compliance, and business integrity.

Beijing Customs AEO Advanced Certification

The Customs AEO (Authorized Economic Operator) Advanced Certification is the highest credit rating in the customs credit management system. It allows for the use of 22 preferential policies in five categories by customs and 49 joint incentive measures implemented by relevant national departments. Additionally, it enables the use of 52 customs clearance facilitation measures from AEO-recognized countries or regions. This certification plays a positive role for enterprises in enhancing international export credibility, strengthening overseas supply chain security, and enhancing product competitiveness globally¹.

The meeting introduced the progress of the cultivation and certification of advanced customs enterprises in Beijing in 2023. It also extensively explained AEO-related policies, covering various aspects such as enterprise management measures, credit management policies, and measures for reform in bonded zones. The event included the issuance of AEO certificates to newly certified enterprises to encourage them to play a more active role in optimizing the business environment.

Mr. Du Kai, CEO of Gan & Lee, stated in his speech at the meeting, "As a pharmaceutical company based in China and with a global footprint, we are honored to receive this certification. It not only reflects the competitive advantage of Gan & Lee's business but also fully recognizes the company's outstanding management and compliance practices in the international trade arena. More than half of Gan & Lee's overseas clients are located in countries recognized by this certification, so it will help us further improve supply chain efficiency, reduce logistics and customs clearance costs, and provide more efficient services to overseas customers. At the same time, the company has established a rigorous internal control system, laying a solid foundation for sustainable and healthy development".

Mr. Du Kai, CEO of Gan & Lee Pharmaceuticals, speaking at the conference

It is reported that in 2023, only 12 companies in Beijing have obtained the advanced customs certification. Achieving this certification will help Gan & Lee build a high-quality international network, including countries along the Belt and Road. In the future, Gan & Lee will continue to improve its management level, consistently uphold the principles of integrity, compliance，and innovation, and serve global partners with a high sense of responsibility, thus promoting the healthy development of China's international trade.

Reference：

1.     綜保區又一企業獲得AEO高級認證企業資格！https://www.cdht.gov.cn/cdht/c152114/2023-03/03/content_c4025bbc2ed9439da892c499c76dc315.shtml

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^?), fast-acting lispro injection (Prandilin^?), fast-acting aspart injection (Rapilin^?), mixed protamine zinc lispro injection (25R) (Prandilin^?25), aspart 30 injection (Rapilin^?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^?).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.